D-0432-2023 Class II Terminated
FDA drug recall D-0432-2023 was initiated by The Harvard Drug Group on Feb 23, 2023 and is designated Class II. Reason for recall: Packaging defect: observed packaging defect, blister packaging inadequately sealed. The recall status is terminated (terminated Apr 30, 2024). Affected quantity: 17,586 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 8, 2023
- Initiation Date
- Feb 23, 2023
- Termination Date
- Apr 30, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 17,586 cartons
Product description
Carbidopa and Levodopa Tablets, USP 25 mg/100 mg, 10x10 Unit Dose carton, Rx Only, Manufactured in Czech Republic by: Teva Czech Industries, s.r.o. Opava-Komarov, Czech Republic, Manufactured for: Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, Packaged and Distributed by: Major Pharmaceuticals Indianapolis, IN 46268 USA. NDC 0904-7257-61, UPC 3 09047 25761 4
Reason for recall
Packaging defect: observed packaging defect, blister packaging inadequately sealed.
Distribution pattern
Distributed Nationwide in the USA
Code information
Lot: M04145 Exp. 01/2024
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0432-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026